Federal court sides with DEA’s denial of access to psilocybin for terminally ill patients; COMPASS trigger law in Kansas; Could Arizona be first on ibogaine? - The Microdose | Substack
Federal court upheld DEA's denial of access to psilocybin for terminally ill patients, reinforcing strict Schedule I controls. Kansas enacted a trigger law for COMPASS pathways, and Arizona may pioneer ibogaine regulation. These developments signal continued federal restrictions on psychedelics but potential state-level shifts.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) involved in psychedelic research or production. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Ongoing; immediate review of compliance status recommended.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
DEA's denial of psilocybin access for terminally ill patients was upheld, maintaining Schedule I status. Kansas trigger law may allow future COMPASS access. Arizona could become first state to regulate ibogaine.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) involved in psychedelic research or production.
What you must do
Review current and planned psychedelic-related activities for compliance with federal Schedule I restrictions. Monitor state-level developments in Kansas and Arizona for potential regulatory changes.
Deadline
Ongoing; immediate review of compliance status recommended.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)